Obinutuzumab for the treatment of chronic lymphocytic leukemia

Drugs of Today

Volumn 50, Issue 6, 2014, Pages 407-419

  Rogers, K A ^a   Jones, Jeffrey ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Anti CD20; Apoptosis inducers; Chronic lymphocytic leukemia; GA 101; Leukemia; Obinutuzumab

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTIHISTAMINIC AGENT; BENDAMUSTINE; CD20 ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OFATUMUMAB; PARACETAMOL; RITUXIMAB; VENETOCLAX;

ANEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEVER; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; INFECTION; INFUSION RELATED REACTION; LYMPHOCYTE DEPLETION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREMEDICATION; PROGRESSION FREE SURVIVAL; REMISSION; RISK REDUCTION; SECOND CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT;

ANTI-CD20; APOPTOSIS INDUCERS; CHRONIC LYMPHOCYTIC LEUKEMIA; GA-101; LEUKEMIA; OBINUTUZUMAB;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; DISEASE-FREE SURVIVAL; DRUG INTERACTIONS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PATIENT SAFETY; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903754211     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.6.2138702     Document Type: Article

References (63)

1. Dores, G.M., Anderson, W.F., Curtis, R.E. et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007, 139(5): 809-19. (Pubitemid 350115721)
2. Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., Catovsky, D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998, 51(5): 364-9. (Pubitemid 28289122)
3. Hallek, M., Cheson, B.D., Catovsky, D. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111(12): 5446-56.
4. Zent, C.S., Kyasa, M.J., Evans, R., Schichman, S.A. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer 2001, 92(5): 1325-30.
5. Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N., Pasternack, B.S. Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46(2): 219-34.
6. Binet, J.L., Lepoprier, M., Dighiero, G. et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977, 40(2): 855-64. (Pubitemid 8177910)
7. Foon, K.A., Boyiadzis, M., Land, S.R. et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27(4): 498-503.
8. Eichhorst, B., Goede, V., Hallek, M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009, 50(2): 171-8.
9. Catovsky, D., Else, M., Richards, S. Chlorambucil-still not bad: a reappraisal. Clin Lymphoma Myeloma Leuk 2011, 11(Suppl. 1): S2-6.
10. Dighiero, G., Maloum, K., Desablens, B. et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998, 338(21): 1506-14.
11. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood 1990, 75(7): 1414-21.
12. Eichhorst, B.F., Busch, R., Stilgenbauer, S. et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009, 114(16): 3382-91.
13. Rai, K.R., Peterson, B.L., Appelbaum, F.R. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343(24): 1750-7.
14. Flinn, I.W., Neuberg, D.S., Grever, M.R. et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007, 25(7): 793-8. (Pubitemid 350002879)
15. Eichhorst, B.F., Busch, R., Hopfinger, G. et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107(3): 885-91. (Pubitemid 43156283)
16. Catovsky, D., Richards, S., Matutes, E. et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007, 370(9583): 230-9. (Pubitemid 47069536)
17. Nadler, L.M., Ritz, J., Hardy, R., Pesando, J.M., Schlossman, S.F., Stashenko, P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981, 67(1): 134-40. (Pubitemid 11163165)
18. Jaglowski, S.M., Byrd, J.C. Rituximab in chronic lymphocytic leukemia. Semin Hematol 2010, 47(2): 156-69.
19. Byrd, J.C., Rai, K., Peterson, B.L. et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105(1): 49-53.
20. Hallek, M., Fischer, K., Fingerle-Rowson, G. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376(9747): 1164-74.
21. Plosker, G.L., Figgitt, D.P. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003, 63(8): 803-43. (Pubitemid 36432084)
22. Beers, S.A., Chan, C.H., French, R.R., Cragg, M.S., Glennie, M.J. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010, 47(2): 107-14.
23. Glennie, M.J., French, R.R., Cragg, M.S., Taylor, R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007, 44(16): 3823-37. (Pubitemid 47332625)
24. Niederfellner, G., Lammens, A., Mundigl, O. et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011, 118(2): 358-67.
25. Mossner, E., Brunker, P., Moser, S. et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010, 115(22): 4393-402.
26. Nguyen, D.T., Amess, J.A., Doughty, H., Hendry, L., Diamond, L.W. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999, 62(2): 76-82. (Pubitemid 29071265)
27. Byrd, J.C., Murphy, T., Howard, R.S. et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001, 19(8): 2153-64. (Pubitemid 32366969)
28. O'Brien, S.M., Kantarjian, H., Thomas, D.A. et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19(8): 2165-70. (Pubitemid 32366970)
29. Barth, M.J., Czuczman, M.S. Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia. Future Oncol 2013, 9(12): 1829-39.
30. Pawluczkowycz, A.W., Beurskens, F.J., Beum, P.V., Lindorfer, M.A., van de Winkel, J.G., Parren, P.W., Taylor, R.P. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009, 183(1): 749-58.
31. Wierda, W.G., Kipps, T.J., Mayer, J. et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010, 28(10): 1749-55.
32. Lemery, S.J., Zhang, J., Rothmann, M.D. et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 2010, 16(17): 4331-8.
33. Fischer, K., Cramer, P., Busch, R. et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012, 30(26): 3209-16.
34. Wierda, W.G., Kipps, T.J., Durig, J. et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011, 117(24): 6450-8.
35. Tam, C.S., O'Brien, S., Wierda, W. et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112(4): 975-80.
36. Ogura, M., Hatake, K., Tobinai, K. et al. Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Jpn J Clin Oncol 2013, 43(5): 466-75.
37. th Annu Meet Am Soc Hematol (December 6-9, San Francisco) 2008] 2008, 112(11): Abst 234.
38. st Annu Meet Am Soc Hematol (December 5-8, New Orleans) 2009] 2009, 114(22): Abst 1704.
39. Salles, G., Morschhauser, F., Lamy, T. et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012, 119(22): 5126-32.
40. Salles, G.A., Morschhauser, F., Solal-Celigny, P. et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013, 31(23): 2920-6.
41. Goede, V., Fischer, K., Busch, R. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014, 370(12): 1101-10.
42. st Annu Meet Am Soc Hematol (December 5-8, New Orleans) 2009] 2009, 114(22): Abst 884.
43. Morschhauser, F.A., Cartron, G., Thieblemont, C. et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013, 31(23): 2912-9.
44. rd Annu Meet Am Soc Hematol (December 10-13, San Diego) 2011] 2011, 118(21): Abst 3704.
45. Sehn, L.H., Assouline, S.E., Stewart, D.A. et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012, 119(22): 5118-25.
46. Radford, J., Cartron, G., Morschhauser, F. et al. Obinutu - zumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: final data from the maintenance phase of the phase 1b GAUDI study (BO21000). Blood 2013, 122(21): 1814.
47. Kern, D.J., James, B.R., Blackwell, S., Gassner, C., Klein, C., Weiner, G.J. GA101 induces NK-cell activation and antibodydependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma 2013, 54(11): 2500-5.
48. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., Watier, H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99(3): 754-8. (Pubitemid 34525533)
49. Rafiq, S., Butchar, J.P., Cheney, C. et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol 2013, 190(6): 2702-11.
50. Dalle, S., Reslan, L., Besseyre de Horts, T. et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011, 10(1): 178-85.
51. Ogura, M., Tobinai, K., Hatake, K. et al. Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Cancer Sci 2013, 104(1): 105-10.
52. Morschhauser, A., Salles, A., Cartron, A., Crump, A., Birkett, J., Carlile, A., Sehn, H. Dose selection for phase III studies of the monoclonal anti-CD20 antibody obinutuzumab (GA101) - a rational approach. Haematologica 2011, 96(Suppl. 2): 390.
53. A study comparing RO5072759 (GA101) 1000 mg versus 2000 mg in patients with previously untreated chronic lymphocytic leukemia (GAGE) (NCT01414205). ClinicalTrials.gov Web site. Accessed March 5, 2014.
54. Obinutuzumab Full Prescribing Information [Package Insert]. Genentech, Inc.
55. Morton, L.M., Curtis, R.E., Linet, M.S. et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010, 28(33): 4935-44.
56. Rawstron, A.C., Kennedy, B., Evans, P.A. et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001, 98(1): 29-35.
57. Bottcher, S., Ritgen, M., Fischer, K. et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012, 30(9): 980-8.
58. Moreton, P., Kennedy, B., Lucas, G. et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005, 23(13): 2971-9. (Pubitemid 46224116)
59. O'Brien, S., Kingsley, C.D., Eradat, H., Pagel, J.M., Lymp, J., Hirata, J., Kipps, T.J. Safety and efficacy of obinutuzumab (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): results from the phase 1b Galton trial (GAO4779g). Blood [Annu Meet Am Soc Hematol (December 7-10, New Orleans) 2013] 2013, 122(21): Abst 523.
60. A study of GA101 (RO5072759) in combination with chemotherapy in patients with previously untreated chronic lymphocytic leukemia (GALTON) (NCT01300247). ClinicalTrials.gov Web site. Accessed March 5, 2014.
61. A study of GDC-0199 (ABT-199) in combination with obinutuzumab in patients with chronic lymphocytic ceukemia (NCT01685892). ClinicalTrials.gov Web site. Accessed March 5, 2014.
62. A study evaluating the efficacy of obinutuzumab and bendamustine treatment in patients with refractory or relapsed chronic lymphocytic leukemia (NCT02071225). ClinicalTrials. gov Web site. Accessed March 5, 2014.
63. A safety study of obinutuzumab alone or in combination with chemotherapy in patients with chronic lymphocytic leukemia (NCT01905943). ClinicalTrials.gov Web site. Accessed March 5, 2014.